Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLFGHX)

Drug Name

BRL 35135 Drug Info

Synonyms

Brl35135A; BRL 35135; Methyl 4-(2-(2-hydroxy-2-(3-chlorophenyl)ethylamino)propyl)phenoxyacetate; Brl-35135; 91097-81-3; C20H24ClNO4; Acetic acid, (4-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)phenoxy)-, methyl ester; AC1Q3M3M; AC1L3U5A; CHEMBL49289; SCHEMBL4611391; CTK5G8940; ZFLBZHXQAMUEFS-UHFFFAOYSA-N; LS-178136; L003499; methyl 4-[2-[(3-chloro-beta-hydroxyphenethyl) amino]propyl]phenoxyacetate; [4-[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid methyl ester; methyl 2-[4-[2-[[2-(3-chloroph

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Phase 2	[1]

Cross-matching ID

PubChem CID: 122186
CAS Number: CAS 91097-81-3
TTD Drug ID: DMLFGHX

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Adrenergic receptor beta-1 (ADRB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[3]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[4]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[5]
Atenolol	DMNKG1Z	Angina pectoris	BA40	Approved	[6]
Acebutolol	DM0TI4U	Hypertension	BA00-BA04	Approved	[6]
Metoprolol	DMOJ0V6	Acute coronary syndrome	BA41	Approved	[6]
Timolol	DM3NXRU	High blood pressure	BA00	Approved	[7]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[8]
Betaxolol	DM6EUL5	Hypertension	BA00-BA04	Approved	[9]
Sotalol	DML60TN	Sinus rhythm disorder	BC9Y	Approved	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-1 (ADRB1)	TTR6W5O	ADRB1_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	Acute effects of the beta 3-adrenoceptor agonist, BRL 35135, on tissue glucose utilisation. Br J Pharmacol. 1995 Feb;114(4):888-94.
2	Clinical pharmacology of beta 3-adrenoceptors. Br J Clin Pharmacol. 1996 Sep;42(3):291-300.
3	Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
4	Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
5	Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
6	Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
7	Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
8	Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
9	beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
10	beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.